Mianserin Orifarm

Mianserin, the active ingredient in Mianserin Orifarm, is a tetracyclic antidepressant presented as an oral tablet for oral use. It is prescribed for the treatment of major depressive disorder in adult patients, helping to alleviate depressive symptoms by modulating neurotransmitter activity.

GNH USA supplies Mianserin Orifarm as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. The product complies with EU regulatory standards and is distributed through GNH USA's global logistics network, ensuring quality and traceability for healthcare providers.

Mianserin is a tetracyclic antidepressant that acts on depressive and related mood disorders.

- Major depressive disorder: alleviates depressive symptoms in adults. - Depressive episodes in bipolar disorder: used as an adjunct to stabilize mood. - Anxiety associated with depression: helps reduce anxiety symptoms.

Mianserin may cause a range of adverse reactions, from mild to severe.

Common Side Effects: - Sedation or drowsiness - Weight gain or increased appetite - Dry mouth - Constipation - Dizziness - Orthostatic hypotension

Serious or Rare Side Effects: - Agranulocytosis or severe blood dyscrasias - Seizures - Cardiac arrhythmias - Severe hypotension - Suicidal thoughts or behavior - Hepatotoxicity

Before prescribing Mianserin, clinicians should consider several safety aspects.

- Assess cardiovascular status: evaluate blood pressure and heart rate prior to initiation. - Monitor weight: watch for significant weight gain during therapy. - Screen for suicidal ideation: especially during the early treatment phase. - Avoid abrupt discontinuation: taper the dose under medical supervision to reduce withdrawal risk. - Use caution in hepatic impairment: consider dose adjustment if liver function is compromised. - Store at ambient temperature: keep in the original container, protect from moisture and light.

Mianserin can interact with other medicines, requiring careful management.

Major Interactions (Avoid): - MAO inhibitors: risk of hypertensive crisis. - SSRIs or other serotonergic agents: potential serotonin syndrome. - CNS depressants (e.g., benzodiazepines): enhanced sedation and respiratory depression.

Moderate Interactions (Monitor Closely): - Alcohol: may increase sedative effects. - Anticholinergic drugs: additive dry mouth and constipation.